By now, you are likely aware of many of the well-established risks associated with smoking cigarettes, such as cancer, asthma, chronic obstructive pulmonary disease (COPD), diabetes, cardiovascular disease, and stroke. But did you know that research has discovered a link between smoking and cognitive decline?
This research emphasizes the importance of identifying and controlling modifiable risk factors for cognitive decline and dementia as early as possible while monitoring brain health to detect changes in brain function as early as possible.
Here is everything you need to know about smoking and cognitive decline, including a breakdown of the research and the best way to monitor brain health while controlling modifiable risk factors for dementia.
Over the past two and a half decades, researchers have discovered a significant connection between smoking, cognitive decline, and dementia. Research suggests smoking increases the risk of cognitive decline and dementia and may accelerate cognitive decline in individuals with Mild Cognitive Impairment.
A 2008 study assessing smoking and cognitive decline among middle-aged men and women found that at baseline, people who smoke scored lower than those who have never smoked in global cognitive function, speed, and flexibility. At the five-year follow-up, decline among smokers was 1.9 times greater for memory function, 2.4 times greater for cognitive flexibility, and 1.7 times greater for global cognitive function compared to those who have never smoked. Additionally, smokers who smoked a greater number of cigarettes (measured in pack-years) showed a greater decline in cognitive function.
A 2012 study assessing the impact of smoking on cognitive decline in early old age found that middle-aged male smokers experienced faster cognitive decline when compared to those who have never smoked. In former smokers (with at least a 10-year cessation), no adverse effects on cognitive decline were observed. They also found that cognitive decline did not vary as a function of smoking status in women, though several other studies have produced contradictory findings. For example, a 2021 study found that smoking was associated with impaired verbal learning and memory performance in women more than men.
A 2021 study found that among people with Mild Cognitive Impairment, smokers showed a more rapid decline in functional performance compared to non-smokers, where functional performance refers to the ability to complete Activities of Daily Living (normal day-to-day activities).
Together, this research suggests that there is indeed a relationship between smoking and cognitive decline, though it is not yet clear what role sex plays in this relationship.
Over the years, many studies have assessed the impact of smoking on the risk of developing dementia later in life. A review of 37 research studies assessing the association between smoking, dementia risk, and Alzheimer’s disease risk found that when compared to people who have never smoked, current smokers are 30% more likely to develop dementia and 40% more likely to develop Alzheimer’s disease, the leading cause of dementia. They also concluded that smoking cessation can reduce the risk of developing dementia.
To summarize all of the above research and make this a bit more digestible, here is what research currently suggests:
While there is a clear connection between smoking and cognitive decline, it is not fully clear why it is that smoking affects brain health. However, there are several theories on how smoking damages our brains and increases the risk of developing dementia, including the following:
The connection between smoking and cognitive decline has important implications for individuals who smoke. While smoking is a tough habit to quit, it is a modifiable risk factor for dementia. By taking appropriate steps to control risk factors and regularly monitoring brain health, patients can benefit from early intervention and better health outcomes. In the event a decline in brain function is detected, frequent and consistent monitoring of brain health provides early diagnosis and early treatment.
At Altoida, we are dedicated to providing a reliable, affordable, and accessible way to measure and monitor your brain health. We are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.
By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.
This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. After our Breakthrough Device designation by the FDA, Altoida’s device will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease. In the future, we hope to utilize our technology to diagnose a breadth of neurological diseases.
To learn more about the link between smoking and cognitive decline or about using Altoida’s Precision Neurology platform, contact us today.